New York, USA – February 4, 2021 – BOC Sciences announced that it will comprehensively promote the enhancement of its ADC conjugation technology platform and strengthen its cooperation with global biotechnology companies specializing in the development of antibody-conjugated drugs (ADCs) technology.
Before announcing this news, BOC Sciences had comprehensively laid out its ADC payload and linker development and manufacturing plants last year. This company will combine years of efficient small molecule expertise and advanced ADC technology to develop integrated services & products for existing and potential customers.
An effective antibody-drug conjugate (ADC) must conjugate an effective drug/linker combination to the antibody to determine the optimal amount of drug carried by a single antibody. In addition, the linker must remain stable in the system circulation to minimize adverse effects, but it must be cleaved quickly after the ADC finds its intended target antigen.
BOC Sciences claims that its technology can improve the flexibility of linker design and stabilize the drug-antibody ratio (DAR) to help customers develop ADC drugs with higher efficacy and safety, thereby serving more patients.
About BOC Sciences
The BOC Sciences has always been at the forefront of antibody-drug conjugation and process development. It supports the development of oncology drugs by providing advanced ADC coupling technology, linker development, payload development services, and high-quality cytotoxic small molecule products.
For more information about BOC Sciences, please visit https://adc.bocsci.com.